Goa Among India’s Most Obese States, NFHS-6 Flags Sharp Rise in Lifestyle Diseases

IMT News Desk
IMT News Desk
· 2 min read
Goa ranks among India’s most obese states as NFHS-6 data shows nearly half of adults overweight, with rising diabetes and hypertension burden

Goa has emerged as one of the most obese states in India, with nearly half of its adult population now overweight or obese, according to the latest National Family Health Survey (NFHS-6) 2023-24 data. The survey, released by the Union Ministry of Health and Family Welfare, reports that 45.1% of women and 43.6% of men in Goa have a body mass index (BMI) of 25 kg/m² or above, significantly higher than the national averages of 30.7% for women and 27.3% for men.

The findings mark a steep rise from NFHS-5 (2019-21), when 36.1% of women and 32.6% of men in the state were classified as overweight or obese, underscoring the rapid escalation of lifestyle-related health risks. Alongside obesity, the prevalence of high blood sugar has also surged, with 32.1% of men and 27.5% of women in Goa recording blood sugar levels above 140 mg/dl or being on medication for diabetes, compared to national averages of 20.9% and 17.8%, respectively.

Goa now records the highest prevalence of raised blood sugar among men in the country, marginally ahead of Kerala, which stands at 31.9%. The state has also reported an increase in hypertension, with 27.5% of men found to have elevated blood pressure or be on treatment, against a national average of 22.1%, further highlighting the growing burden of non-communicable diseases.

Health experts attribute the rising trends to sedentary lifestyles, unhealthy diets, increased consumption of processed foods and reduced physical activity, particularly in urban and semi-urban pockets. The NFHS-6 data is expected to prompt policymakers and health authorities to scale up state-level interventions focused on early screening, community awareness, and prevention of obesity, diabetes and hypertension to curb Goa’s mounting lifestyle disease burden.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk